Arch Therapeutics Inc (OTCBB:ARTH) Gathers Downward Momentum

[[tagnumber 0]][[tagnumber 1]]After a couple of decent upwards run that Arch Therapeutics Inc (OTCBB:ARTH) experienced in July and August we saw the ticker begin to lost altitude. The daily volumes also dropped and it didn’t seem like the company was too keen to regain its lost value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]That was seen in the lack of press releases lately, but [[tagnumber 6]]ARTH[[tagnumber 7]] still managed to become a bit more stable above the 25 cent per share mark. The company itself is your typical OTC biotech when you look at the numbers contained in the latest quarterly report.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $3.2 million[[tagnumber 13]] [[tagnumber 12]]total assets: $3.3 million[[tagnumber 13]] [[tagnumber 12]]total current liabilities: $1.8 million[[tagnumber 13]] [[tagnumber 12]]total liabilities: $9.3 million[[tagnumber 13]] [[tagnumber 12]]revenues: ZERO[[tagnumber 13]] [[tagnumber 12]]net loss: $1.8 million[[tagnumber 13]] [[tagnumber 24]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Meanwhile, the company’s market value isn’t that big compared to other OTC biotech entities. However, the ticker is losing altitude. Friday saw [[tagnumber 6]]ARTH[[tagnumber 7]] lose another 8.66% of its value and close the day with a price of $0.233 while a total of 1.24 million shares generated a daily dollar volume of $302 thousand.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The lack of press releases or any other news surrounding the company is leading it to a bad start of this week as well. As of the writing of this article [[tagnumber 6]]ARTH[[tagnumber 7]] is already 11.42% down in today’s trading. It looks like the company stock is going through a rough patch so you better be sure to do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]